Cellular/Amniotic-ECM Solutions

About PUR Biologics

PUR Biologics is a clinical-stage biotechnology company developing next-generation biologic products for the multi-billion-dollar orthopedic and spinal regenerative medicine markets. Founded in 2018, the company's strategy is built on a diversified platform of human tissue allografts, synthetic scaffolds, and cellular/amniotic technologies aimed at promoting bone growth, cartilage repair, and disc regeneration. As a key subsidiary of the publicly traded entity HippoFi (ORHB), PUR Biologics aims to commercialize advanced delivery systems like Active Orb and Vital-Mobile while progressing its pipeline toward addressing significant unmet needs in joint preservation and spinal health.

Therapeutic Areas